Ardent Health Partners, Inc. (ARDT) Stock Forecast & Price Target

Compare

92 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARDT Analyst Ratings

Moderate Buy

8 Buy

4 Hold

1 Sell

Based on 13 analysts giving stock ratings to

Ardent

Health Partners, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARDT Stock 12 Month Forecast

Average Price Target

$13.96

▲(57.38% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Ardent Health Partners, Inc. in the last 3 months. The average price target is $13.96 with a high forecast of $17.00 and a low forecast of $10.00. The average price target represents a 57.38% change from the last price of $8.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","18":"$18","11.25":"$11.25","13.5":"$13.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,11.25,13.5,15.75,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.56,14.747692307692308,14.935384615384615,15.123076923076923,15.310769230769232,15.49846153846154,15.686153846153847,15.873846153846154,16.06153846153846,16.24923076923077,16.436923076923076,16.624615384615385,16.81230769230769,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.56,14.513846153846155,14.467692307692309,14.421538461538463,14.375384615384617,14.32923076923077,14.283076923076925,14.236923076923077,14.19076923076923,14.144615384615385,14.098461538461539,14.052307692307693,14.006153846153847,{"y":13.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.56,14.20923076923077,13.858461538461539,13.507692307692308,13.156923076923077,12.806153846153846,12.455384615384617,12.104615384615386,11.753846153846155,11.403076923076924,11.052307692307693,10.701538461538462,10.350769230769231,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.35,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.97,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.00

Average Price Target$13.96

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Benjamin Rossi

J.P. Morgan

$15→$12

Hold

35.29%

Upside

Reiterated

11/24/25

Ardent Health price target lowered to $12 from $15 at JPMorganArdent Health price target lowered to $12 from $15 at JPMorgan

Ann Hynes

Mizuho Securities

$20→$13

Buy

46.56%

Upside

Reiterated

11/18/25

Ardent Health price target lowered to $13 from $20 at MizuhoArdent Health price target lowered to $13 from $20 at Mizuho

A.J. Rice

UBS

$17→$14.5

Buy

63.47%

Upside

Reiterated

11/17/25

Ardent Health price target lowered to $14.50 from $17 at UBSArdent Health price target lowered to $14.50 from $17 at UBS

Jason Cassorla

Guggenheim

$18→$15

Buy

69.11%

Upside

Reiterated

11/17/25

Ardent Health price target lowered to $15 from $18 at GuggenheimArdent Health price target lowered to $15 from $18 at Guggenheim

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Downgraded

11/16/25

Cautious Outlook on Ardent Health Partners, Inc. Amidst Uncertainty in Financial Projections and Rising Costs

David S Macdonald

Truist Financial

$21→$13

Buy

46.56%

Upside

Reiterated

11/14/25

Analysts Conflicted on These Healthcare Names: Ardent Health Partners, Inc. (NYSE: ARDT), Centessa Pharmaceuticals (NASDAQ: CNTA) and Cross Country Healthcare (NASDAQ: CCRN)

Scott Fidel

Goldman Sachs

$19→$12

Hold

35.29%

Upside

Reiterated

11/14/25

Ardent Health price target lowered to $12 from $19 at Goldman SachsArdent Health price target lowered to $12 from $19 at Goldman Sachs

Craig Hettenbach

Morgan Stanley

$12

Hold

35.29%

Upside

Downgraded

11/14/25

Cautious Hold on Ardent Health Partners Amidst Guidance Cuts and Competitive Disadvantages

Ben Hendrix

RBC Capital

$21→$16

Buy

80.38%

Upside

Reiterated

11/14/25

RBC Capital Sticks to Its Buy Rating for Ardent Health Partners, Inc. (ARDT)

Whit Mayo

Leerink Partners

$16

Buy

80.38%

Upside

Reiterated

11/14/25

Ardent Health Partners, Inc.: Buy Rating Affirmed Amid Low Valuation and Cost-Saving Potential

Raj Kumar CFA

Stephens

$14.05→$17

Buy

91.66%

Upside

Assigned

11/14/25

Stephens Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

Timothy Greaves

Loop Capital Markets

$17

Buy

91.66%

Upside

Reiterated

11/14/25

Loop Capital Markets Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

Kevin Fischbeck

Bank of America Securities

$12→$10

Sell

12.74%

Upside

Reiterated

11/13/25

Ardent Health Partners, Inc.: Persisting Financial Challenges Lead to Downgraded Outlook and Underperform Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Benjamin Rossi

J.P. Morgan

$15→$12

Hold

35.29%

Upside

Reiterated

11/24/25

Ardent Health price target lowered to $12 from $15 at JPMorganArdent Health price target lowered to $12 from $15 at JPMorgan

Ann Hynes

Mizuho Securities

$20→$13

Buy

46.56%

Upside

Reiterated

11/18/25

Ardent Health price target lowered to $13 from $20 at MizuhoArdent Health price target lowered to $13 from $20 at Mizuho

A.J. Rice

UBS

$17→$14.5

Buy

63.47%

Upside

Reiterated

11/17/25

Ardent Health price target lowered to $14.50 from $17 at UBSArdent Health price target lowered to $14.50 from $17 at UBS

Jason Cassorla

Guggenheim

$18→$15

Buy

69.11%

Upside

Reiterated

11/17/25

Ardent Health price target lowered to $15 from $18 at GuggenheimArdent Health price target lowered to $15 from $18 at Guggenheim

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Downgraded

11/16/25

Cautious Outlook on Ardent Health Partners, Inc. Amidst Uncertainty in Financial Projections and Rising Costs

David S Macdonald

Truist Financial

$21→$13

Buy

46.56%

Upside

Reiterated

11/14/25

Analysts Conflicted on These Healthcare Names: Ardent Health Partners, Inc. (NYSE: ARDT), Centessa Pharmaceuticals (NASDAQ: CNTA) and Cross Country Healthcare (NASDAQ: CCRN)

Scott Fidel

Goldman Sachs

$19→$12

Hold

35.29%

Upside

Reiterated

11/14/25

Ardent Health price target lowered to $12 from $19 at Goldman SachsArdent Health price target lowered to $12 from $19 at Goldman Sachs

Craig Hettenbach

Morgan Stanley

$12

Hold

35.29%

Upside

Downgraded

11/14/25

Cautious Hold on Ardent Health Partners Amidst Guidance Cuts and Competitive Disadvantages

Ben Hendrix

RBC Capital

$21→$16

Buy

80.38%

Upside

Reiterated

11/14/25

RBC Capital Sticks to Its Buy Rating for Ardent Health Partners, Inc. (ARDT)

Whit Mayo

Leerink Partners

$16

Buy

80.38%

Upside

Reiterated

11/14/25

Ardent Health Partners, Inc.: Buy Rating Affirmed Amid Low Valuation and Cost-Saving Potential

Raj Kumar CFA

Stephens

$14.05→$17

Buy

91.66%

Upside

Assigned

11/14/25

Stephens Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

Timothy Greaves

Loop Capital Markets

$17

Buy

91.66%

Upside

Reiterated

11/14/25

Loop Capital Markets Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

Kevin Fischbeck

Bank of America Securities

$12→$10

Sell

12.74%

Upside

Reiterated

11/13/25

Ardent Health Partners, Inc.: Persisting Financial Challenges Lead to Downgraded Outlook and Underperform Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardent Health Partners, Inc.

1 Month

xxx

Success Rate

4/9 ratings generated profit

Average Return

-0.51%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 44.44% of your transactions generating a profit, with an average return of -0.51% per trade.

3 Months

xxx

Success Rate

5/14 ratings generated profit

Average Return

-7.76%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -7.76% per trade.

1 Year

Ben HendrixRBC Capital

Success Rate

0/10 ratings generated profit

Average Return

-29.20%

reiterated a buy rating 22 days ago

Copying Ben Hendrix's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -29.20% per trade.

2 Years

xxx

Success Rate

0/9 ratings generated profit

Average Return

-36.64%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -36.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARDT Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARDT has received 21 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. ARDT average Analyst price target in the past 3 months is 13.96.

Each month's total comprises the sum of three months' worth of ratings.

ARDT Financial Forecast

ARDT Earnings Forecast

Next quarter’s earnings estimate for ARDT is $0.36 with a range of $0.25 to $0.59. The previous quarter’s EPS was -$0.17. ARDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.

ARDT Sales Forecast

Next quarter’s sales forecast for ARDT is $1.63B with a range of $1.60B to $1.68B. The previous quarter’s sales results were $1.58B. ARDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.

ARDT Stock Forecast FAQ

What is ARDT’s average 12-month price target, according to analysts?

Based on analyst ratings, Ardent Health Partners, Inc.’s 12-month average price target is 13.96.

What is ARDT’s upside potential, based on the analysts’ average price target?

Ardent Health Partners, Inc. has 57.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARDT a Buy, Sell or Hold?

Ardent Health Partners, Inc. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 4 hold ratings and 1 sell ratings.

What is Ardent Health Partners, Inc.’s price target?

The average price target for Ardent Health Partners, Inc. is 13.96. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $10.00. The average price target represents 57.38% Increase from the current price of $8.87.

What do analysts say about Ardent Health Partners, Inc.?

Ardent Health Partners, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of ARDT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ardent Health Partners, Inc. (ARDT) Stock Forecast & Price Target

ARDT Analyst Ratings

ARDT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ardent Health Partners, Inc.

ARDT Analyst Recommendation Trends

ARDT Financial Forecast

ARDT Earnings Forecast

ARDT Sales Forecast

ARDT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts